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A B S T R A C T
Mitochondrial respiratory chain deficiency and mitochondrial DNA deletions are reported in substantia nigra
neurons from healthy aged and Parkinson's disease cases, with extensive neuronal loss only seen in the latter.
This study aimed to understand the pathological relevance of mitochondrial defects for neuronal survival. Using
post-mortem human midbrain, substantia nigra neurons exposed to different types of mitochondrial defects
(including mitochondrial DNA point mutations, single and multiple deletions) were compared to neurons from
healthy aged and Parkinson's disease cases (either sex) at a single neuronal level. We identified mitochondrial
deficiencies in all cases, though these deficiencies were more severe in the mitochondrial disease patients with
multiple deletions. A significant reduction in TFAM expression was detected in Parkinson's disease compared to
cases with other mitochondrial defects. Higher mitochondrial DNA copy number was detected in healthy aged
neurons, despite a deletion level equivalent to Parkinson's disease. Our data support that in individuals with
pathogenic mitochondrial defects, neurons respond to mitochondrial defect to survive and such an adaptation
may involve TFAM.
1. Introduction
Age-related mitochondrial dysfunction is implicated in the degen-
eration of the substantia nigra (SN), where neuronal loss causes the
movement disorder in Parkinson's disease (PD). Mitochondrial re-
spiratory chain (RC) deficiency has been reported in both SN homo-
genate (Pyle et al., 2016; Schapira et al., 1989) and individual SN
neurons (Grunewald et al., 2014; Grunewald et al., 2016) from those
affected by PD, and nigrostriatal degeneration (Tzoulis et al., 2013). In
cytochrome c oxidase (COX)-deficient neurons from aged individuals
and PD patients, the level of mitochondrial DNA (mtDNA) deletion is
strikingly high (~50%) compared to other post-mitotic tissues (Bender
et al., 2006; Kraytsberg et al., 2006). These mtDNA deletions are be-
lieved to be somatically acquired, with different deletions clonally ex-
panded within each SN neuron (Reeve et al., 2008). It is interesting that
the pattern of acquired multiple mtDNA deletions seen in aged and PD
neurons shows consistency with those from patients who carry
mutations in the mitochondrial polymerase (POLG) gene (Nido et al.,
2017; Reeve et al., 2008). Individuals with POLG mutations accumulate
mtDNA deletions with advancing age, and alongside other neurological
symptoms such as ataxia and dementia, some patients may develop
Parkinsonism due to nigrostriatal degeneration (Bandettini di Poggio
et al., 2013; Luoma et al., 2004; Miguel et al., 2014; Rempe et al.,
2016). These findings highlight the potential consequence of clonally
expanded mtDNA mutations and related biochemical defects on the
survival of SN neurons. However, SN neurons appear to exhibit differ-
ential responses to mitochondrial defects, as severe neuronal loss is only
found in PD and some POLG patients (Reeve et al., 2013), whilst this
neuronal population is relatively spared in healthy ageing and in-
dividuals with mitochondrial disease caused by pathogenic mtDNA
point mutations or single deletions (Reeve et al., 2013). These mtDNA
mutations will have been maternally inherited or occurred during
embryonic development, suggesting an adaptive response in SN neu-
rons exposed to mitochondrial defects from the earliest stages of life
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which allows them to survive into later life. Understanding the me-
chanism behind such an adaptive response will be essential for the
future development of PD neuroprotective treatments.
Both total mtDNA copy number and deletion level were recently
found to increase with advancing age in individual SN neurons from
healthy aged individuals (Dolle et al., 2016), with similar changes and
an enhancement of mitochondrial function detected in dopaminergic
neurons from a premature ageing mouse model (Perier et al., 2013).
These data suggest that a response of SN neurons to mitochondrial
dysfunction may be implemented through the adjustment of mi-
tochondrial population maintenance. This responsive mechanism may
be impaired in PD cases, as a decrease in the correlation between
mtDNA copy number and deletion level has been suggested (Dolle et al.,
2016), further supported by the finding of decreased expression of
mitochondrial transcription factor A (TFAM) (Grunewald et al., 2016).
TFAM functions in the maintenance of mtDNA nucleoid structure, is a
critical regulator of mtDNA transcription and primer of mtDNA synth-
esis (Bonawitz et al., 2006).
To validate whether impaired mitochondrial maintenance is only
present in PD neurons, and to explore the potential role of nuclear-
mitochondrial interaction in the regulation of this process, a compre-
hensive comparison of single SN neurons exposed to different types of
mtDNA defect was performed. Neurons from idiopathic PD patients and
healthy aged individuals were compared to mitochondrial disease pa-
tients with mtDNA point mutations or single, large-scale deletions and a
well-preserved SN neuronal population (Reeve et al., 2013). We also
investigated individuals with multiple mtDNA deletions due to nuclear
gene defects affecting mtDNA maintenance, these cases have variable
levels of SN neuronal loss. The selection of patients enabled us to
evaluate the contribution of age, mtDNA mutation type and inheritance
pattern to the response of SN neurons to mitochondrial dysfunction,
whilst identifying which changes are associated only with mitochon-
drial dysfunction and which were additionally associated with neuro-
degeneration.
2. Materials and methods
2.1. Tissue
All post-mortem tissue samples were obtained from the Newcastle
Brain Tissue Resource (NBTR), and their use conformed to the Local
Research Ethics Committee and the United Kingdom Medical Research
Council's Guidelines on the use of tissue in medical research. The study
included 12 cases with clinically and pathologically confirmed mi-
tochondrial disease (mean, 49 years old; five males, seven females).
Seven patients had inherited or early-onset mtDNA mutations, in-
cluding point mutations and a single, large-scale mtDNA deletion and
five patients had acquired multiple mtDNA deletions due to POLG
mutations (n=4), or an unconfirmed nuclear gene mutation at time of
writing. Eight PD patients (mean, 81 years old; seven males, one fe-
male) were included in this cohort, pathological features and details of
mutations are summarised in Table 1. Fifteen control subjects with a
broad age range (mean, 75 years old; nine males, six females) were also
investigated, while age matched controls were sought, it was difficult to
find exact matches to the younger mitochondrial disease cases
(Table 2).
2.2. Multi-label immunofluorescence
Formalin-fixed paraffin-embedded (FFPE) midbrain sections (5 μm)
were used to perform quadruple-label immunofluorescence (IF) (Rocha
et al., 2015). A combination of four antibodies against mitochondrial
proteins, including anti-NDUFB8 (Abcam, ab110242, a nuclear-en-
coded complex I subunit), anti-MTCOI (Abcam, ab14705, a mitochon-
drial-encoded complex IV subunit), mitochondrial mass marker anti-
porin (VDAC1, Abcam, ab14734) and anti-TFAM (Abcam, ab176558)
was employed to assess the relationship between TFAM and mi-
tochondrial deficiency. The presence of neuromelanin and a clear nu-
cleus in brightfield images were used to identify individual SN neurons.
Healthy aged (n=15, neurons counted= 695), point mutation (n=4,
neurons= 183), single, large-scale mtDNA deletion (n= 1, neu-
rons= 50), multiple mtDNA deletion (n=5, neurons= 233) and PD
(n=7, neurons= 265) cases were included.
A second antibody cocktail of anti-PGC-1α (Millipore, ab3242),
anti-COXIV (Abcam, ab14744, a nuclear-encoded complex IV core
subunit), anti-porin and anti-tyrosine hydroxylase (TH, Sigma, T2928),
a dopaminergic neuronal marker (Sigma, T2928) was employed to as-
sess changes in mitochondrial biogenesis signalling. Healthy aged
(n= 15, neurons= 558), point mutation (n=6, neurons= 267),
single, large-scale mtDNA deletion (n= 1, neurons= 46), multiple
mtDNA deletion (n=5, neurons= 188) and PD (n= 7, neu-
rons= 242) cases were included.
Fluorescent secondary antibodies applied in this study included
Alexa Fluor®488 (A11008), Alexa Fluor® 647 (A21240), Alexa Fluor®
546 (A21133), Alexa Fluor® 350 (A21140), anti-mouse IgG1 Biotin-XX
(A10519) and Streptavidin Alexa Fluor® 647 conjugated (S32357).
Imaging and mean densitometric measurement were performed,
blinded for diseases status, with an Apotome Axio Imager Z2 micro-
scope and Zen Blue software (Carl Zeiss).
2.3. Laser-microdissection of single neurons
For single neuron DNA extraction, frozen midbrain sections at
15 μm thickness were stained for TFAM, COXIV, TH and Hoechst
(25 μg/ml) using a similar multi-label IF assay as above. Tiled images
were captured by Zen Blue in Axio Imager M1 microscope (Carl Zeiss)
in order to map individual TH-positive neurons within the SN.
Densitometric values of COXIV and TFAM signal were obtained for the
dissected neurons. Imaged cryosections were prepared for laser mi-
crodissection by removing coverslips and dehydrating through an as-
cending ethanol gradient (70%, 95%, 100%, and 100% v/v). The neu-
rons of interest were outlined based on their TH signal in the 488 nm
channel and laser-captured using the PALM laser micro-dissection
system (Zeiss). For each section, over 25 single neurons were captured
and collected individually in 10 μl of Tris-Tween lysis buffer (0.5M
Tris- HCl, 0.5% Tween- 20, 1% Proteinase K, pH 8.5). Single cells were
lysed for 2 h at 55 °C, followed by 10min at 95 °C.
2.4. Triplex real-time PCR
The triplex real-time PCR assay was performed using previously
optimized primers for MT-ND1, MT-ND4 and D-loop (Rygiel et al.,
2015). Major arc and minor arc mtDNA deletions were determined as
previously (Rygiel et al., 2015). A threshold level of 33.33% is used to
define the presence of deletions when MT-ND1/D-Loop or MT-ND4/D-
Loop deletion levels are calculated (Rygiel et al., 2015). For individual
TH-positive neurons, total mtDNA copy number was determined by D-
Loop copy number (per area), andMT-ND4 copy number (per area) was
used as the wild type (non-MT-ND4 deleted) copy number metric.
Correlation between mitochondrial copy number and TFAM expression
within individual captured neurons were also performed via matching
of mapped neurons. Individual TH-positive neurons from healthy aged
(n=8, neurons= 175); point mutation (n=4, neurons= 55); single,
large-scale deletion (n=1, neurons= 26); multiple deletion (n=3,
neurons= 58) and PD (n=6, neurons= 119) cases were investigated.
2.5. Statistical analysis
Densitometric values of fluorescent signal within the SN neurons
was background corrected using no-primary controls and log-trans-
formed for normalisation. Expression levels of complex I, complex IV
and TFAM were normalized to mitochondrial mass (the level of porin)
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3
and represented as z scores for individual neurons. The z scores were
determined by the standard deviation of each neuron from the range of
the neuronal population from healthy aged individuals (Rocha et al.,
2015). Categorization of protein expression level was defined using z
scores:<−2 as deficiency; −1 to −2 as reduction;> − 1 as normal.
Due to the fact that these parameters were set based on the data dis-
tribution of all control cases, what we established here is a semi-
quantitative measure of protein expression level.
Statistical analyses were performed using Graph Pad Prism (v.8.0.1)
and R (Team, 2018) software. Differences between groups in terms of
protein expression and mtDNA copy number were assessed by one-way
ANOVA. The Spearman rank correlation coefficient (r2) and associated
p value were used in correlative analysis of protein targets. Differences
between the correlative relationships were assessed by comparison of
regression slope and correlation coefficients. Frequency distributions
were calculated to describe the parameters of mtDNA maintenance.
3. Results
3.1. Expression of respiratory chain subunits in SN neurons with differing
mitochondrial DNA defects
Using quadruple immunofluorescence on human formalin-fixed,
paraffin-embedded (FFPE) midbrain sections, SN neurons were labelled
for NDUFB8, MTCOI, porin and TFAM simultaneously. Examples of four
of the eight different categories of relative complex I and complex IV
abundance have been highlighted using neurons from two POLG cases
(Fig. 1a). The categories were determined based on the gradual increase
in fluorescent intensity in neurons (between deficient and positive),
with a ranking ranging from deficient in both complex I and complex IV
to normal expression of both. The categories of protein expression were
objectively defined by the z score distribution (>−1 as normal,−2 to
−1 reduced and < −2 deficient). The eight groups of neurons were
then expressed as a percentage of the total number of neurons counted
in each case (mean count, n=45 neurons per case, Fig. 1b).
The total number of neurons with decreased complex I and/or
complex IV was the highest in patients with multiple mtDNA deletions.
The highest level of combined deficiency was found in POLG1, with
27.3% of neurons showing a combined complex I and complex IV de-
ficiency, 27.3% showing CI deficiency and 9.09% complex IV defi-
ciency. In the patient with multiple mtDNA deletions for which the
nuclear genetic cause was undetermined, there was 6.67% combined
deficiency, 3.33% complex I deficiency and 18.3% complex IV defi-
ciency. There was a high level of isolated complex I deficiency in the
patient with a single, large-scale mtDNA deletion (64.0% deficiency and
34.0% reduction). This mtDNA deletion affects complex I subunit genes
but not complex IV genes (Rocha et al., 2018). The point mutation cases
mainly exhibited complex I reduction, with or without a corresponding
decrease in complex IV expression, with only 2.1% complex IV deficient
neurons with complex I reduction in MERRF1. These changes in com-
plex I and complex IV expression are consistent with results obtained
using single-label immunohistochemistry (overlapping cases labelled in
Table 1) (Reeve et al., 2013).
We could also examine these deficiencies in detail in PD cases and
controls. There was evidence of complex I and complex IV deficient
neurons in PD cases, with complex I more severely affected than com-
plex IV. Interestingly, neurons with both complex I and complex IV
deficiency were sparsely found, suggesting that these cells may have
degenerated during the progression of the disease. A small percentage
of complex I and complex IV deficient neurons was detected in the
healthy aged SN populations. Overall as for the PD cases, there was
more complex I deficiency and reduction than complex IV loss (Fig. 1c-
d).
3.2. Changes in TFAM expression in SN neurons with different
mitochondrial defects
Next, we investigated alterations in TFAM expression, determined
by z score, in SN neurons with different mtDNA mutations (Fig. 2a).
There was a significant increase in TFAM expression in patients with
mtDNA point mutations and multiple deletions compared to controls (F
(4, 1359) =49.26, p= .0078, point mutations; p= .0003, multiple
deletions, ANOVA), however, the controls were much older (Fig. 2b).
PD neurons showed significantly lower TFAM expression than neurons
from all the other four groups (F (4, 1359) =49.26, p < .0001,
ANOVA), suggesting this adaptive neuronal response may be impaired
in PD cases. This trend was nicely reproduced in those neurons with
reduced complex I expression (Fig. 2c), where TFAM expression was
significantly lower in patients with PD than the others (F (4, 292)
=45.58, p < .0001, ANOVA).
3.3. MtDNA deletion levels in single TH-positive neurons
To ascertain whether the observed changes in TFAM expression
were also associated with altered mtDNA homeostasis in SN neurons,
we measured both mtDNA copy number and deletion level in individual
neurons from all groups. Only total copy number data was obtained in
cases with mtDNA point mutations, due to the absence of deletion, and
the threshold of point mutation heteroplasmy was reported to be much
higher than that of deletions (Moslemi et al., 1998; Reeve et al., 2013).
As expected, MT-ND4 deletions were detected in healthy aged TH-po-
sitive neurons, (mean age 74.5 years, n=8, total counted
Table 2
Summary of control cases for this study. Labelled cases (#) were included in the molecular study due to available frozen sections. COPD -Chronic obstructive
pulmonary disease.
Controls Sex Age (years) Post mortem delay (hours) Cause of death Substantia nigra pathology
Con 1# F 59 34 Multi-organ failure Very mild age associated loss of pigmented neurons
Con 2# M 60 60 Haemorrhage Mild age associated loss of pigmented neurons
Con 3 M 66 56 Exacerbation of COPD Mild age associated loss of pigmented neurons
Con 4# M 70 72 Metastatic prostate cancer Mild age associated loss of pigmented neurons
Con 5 M 71 25 Sigmoid adenocarcinoma Very mild age associated loss of pigmented neurons
Con 6 F 71 72 Pneumonia Mild age associated loss of pigmented neurons
Con 7 F 69 16 Gastric cancer Normal pigmentation with a small amount of extra neuronal neuromelanin
Con 8# M 73 22 Metastatic prostate cancer Mild age associated loss of pigmented neurons
Con 9 M 55 41 Liver cancer Very mild age associated loss of pigmented neurons
Con 10# F 74 67 Lung cancer Mild age associated loss of pigmented neurons
Con 11 M 84 45 Unknown Mild age associated loss of pigmented neurons
Con 12 F 87 33 Intracerebral haemorrhage Mild age associated loss of pigmented neurons
Con 13# M 93 73 Unknown Mild age associated loss of pigmented neurons
Con 14# M 93 53 Pneumonia and cardia failure Mild age associated loss of pigmented neurons
Con 15# Female 93 12 Oesophageal adenocarcinoma Mild age associated loss of pigmented neurons
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neurons= 175) with the deletion level generally falling between
40%–80% (Fig. 3a). Comparable deletion levels were found in the cases
with multiple mtDNA deletions (mean age 65.3 years, n=3, counted
neurons= 58) and PD (mean age 81.2 years, n=6, counted neu-
rons= 119). In the single, large-scale mtDNA deletion patient (age
40 years, counted neurons 26), the level of deletion load was higher and
fell within a smaller range (Fig. 3a). Prominent MT-ND1 deletions
(60%–80%) were also detected in neurons from multiple deletion cases
(Reeve et al., 2008), most of which came from the POLG2 case (Fig. 3b).
SN neurons from ageing controls and PD cases also showed MT-ND1
deletions, however the level was much lower.
3.4. Multiplex analysis of mtDNA copy number changes in TH-positive
neurons
Total copy number was significantly lower in patients with mtDNA
point mutations, multiple mtDNA deletions and PD, compared to aged
controls (F (4, 428) =5.883, p= .0071, point mutation; p= .0001,
multiple deletion; p= .0306, PD, ANOVA; Fig. 3c). For wild type (non-
MT-ND4 deleted) copy number, a significant decrease was seen in the
cases with single mtDNA deletion and multiple mtDNA deletions, which
is more likely a combined consequence of low total copy number and
high deletion load (Fig. 3d). The data show evidence of mtDNA de-
pletion in PD neurons, however large individual diversity was seen in
these cases, for example PD2 and PD4 demonstrate relative high copy
Fig. 1. Analysis of electron transport chain subunits expression. Immunofluorescence images of individual SN neurons from formalin-fixed, paraffin-embedded
(FFPE) human midbrain section (selected from mitochondrial patients POLG1 and 2), demonstrating varying combinations of complex I (CI) and complex IV (CIV)
expression: both CI and CIV deficiency (labelled in dark red), CI deficiency with CIV reduction (red), CI deficiency with CIV reduction (orange), CIV deficiency with
CI reduction (dark yellow), both CI and CIV reduction (yellow), CI reduction with normal CIV (green), CIV reduction with normal CI (blue), and normal expression of
both CI and CIV (dark blue). The categories of protein expression were objectively defined by the z score distribution (> 1 as normal, 2 to 1 reduced and <2
deficient). Cell boundaries were defined based on the porin signal, neurons were only included in analysis if they showed the presence of neuromelanin and a nucleus
on brightfield imaging. Neuromelanin appears as a dark black pigment in these images due to Sudan black counterstaining. Images of single neurons are zoomed in
regions from a x40 magnification image (a). Numbers of neurons within each category are presented as a percentage of the total counted neurons in each case (b) and
group (c-d). Scale bar, 20 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 2. Analysis of TFAM expression at single neuron level. Immunofluorescence images of TFAM staining in individual, neuromelanin containing SN neurons. Cell
boundaries were defined based on the porin signal, neurons were only included in analysis if they showed the presence of neuromelanin and a nucleus on brightfield
imaging. Neuromelanin appears as a dark black pigment in these images due to Sudan black counterstaining. Images of single neurons are zoomed in regions from a
x40 magnification image. Scale bar, 5 μm (a). TFAM expression were compared among the total SN neuronal population and the SN neurons with complex I reduction
(z score < 1) (p < .0001). Each point represents a single TH-positive neuron. Error bars show mean ± SEM (b-c).
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number whereas PD3 and PD7 showed the reverse (Fig. 3-1). Using the
average level of complex I and complex IV expression, we demonstrated
a significant non-linear regression between the proportion of RC normal
neurons and wild type mtDNA copy number in the available cases ex-
cluding those with mtDNA point mutations (df=14, r2=55.53%,
One-phase decay; Fig. 3e). It is interesting that this relationship did not
reappear within RC expression and mtDNA deletion load (Fig. 3f).
3.5. Investigation of mitochondrial biogenesis
Expression of TFAM is closely regulated by peroxisome proliferator-
activated receptor gamma coactivator-1 alpha (PGC-1α and its tran-
scription coactivators. We therefore measured the expression of PGC-1α
alongside two markers for mitochondrial mass (porin and COXIV) in
individual TH-positive neurons (Fig. 4a). No obvious changes in
Fig. 3. Analysis of mtDNA homeostasis. Deletion load of MT-ND4 and MT-ND1 (a-b), alongside total and wild type (non-MT-ND4 deleted) mtDNA copy number (c-d)
were measure in individual TH-positive neurons (*p < .05; **p < .01; ***p < .0001). Each point represents a single TH-positive neuron; Bars shows the
mean ± SEM. (e) A one phase decay (non-linear) regression was demonstrated between ETC subunits expression (represented by the number of neurons with normal
CI/CIV expression) and the wild type mtDNA copy number (r2=55.5%), (f) yet such correlation was not showed with mtDNA deletion (MT-ND4) load.
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mitochondrial mass within individual neurons were observed between
groups, based on the level of porin and COXIV expression (Fig. 4b-c).
There is a lower level of PGC-1α expression in TH-positive neurons in
multiple mtDNA deletions and PD, which was not found to be statisti-
cally significant (Fig. 4d). A decline in PGC-1α expression with ad-
vancing age was also found in healthy ageing cases (r2=29.19%), and
such a correlation was not seen with changes in mitochondrial mass
(Fig. 4e). However, given the lack of young individuals in this study, it's
impossible to trace the actual alterations in PGC-1α expression over a
human life time, therefore difficult to interpret the correlation between
age and mitochondrial biogenesis.
In addition, PD neurons demonstrated the weakest correlation
(r2=7.66%) between PGC-1α and porin expression among all group
studied (mtDNA point mutations (r2=45.15%), multiple deletions
(r2=19.43%) and healthy ageing (r2=34.39%)) (Supplementary
Fig. 4–1). This correlative relationship was significantly different, in
terms of both regression slope and correlation coefficient, between in-
dividuals with PD and healthy aged individuals (p= .024, z
score= 5.12). There was no significant correlation observed between
the average level of PGC-1α and TFAM expression from the two batches
of immunostaining (Supplementary Fig. 4–2).
4. Discussion
Our primary objective was to understand the response of dopami-
nergic neurons to different types of mitochondrial defect. This was
achieved through investigation of mitochondrial RC subunit expression,
mtDNA homeostasis, and via analysis of TFAM expression the potential
regulatory mechanism behind this neuronal response. Although mi-
tochondrial RC phenotypes and mtDNA homeostasis within SN neurons
has been investigated in several post-mortem studies (Flones et al.,
2018; Grunewald et al., 2016; Reeve et al., 2013, 2008; Tzoulis et al.,
Fig. 4. Expression of mitochondrial biogenesis related proteins. Immunofluorescence images of PGC-1α, COXIV, Porin and TH staining in the SN. Scale bar, 50 μm
(a). Average level of COXIV, Porin and PGC-1α expression were compared between groups (b-d). PGC-1α expression showed an aged-related decline (e). Each point
represents the mean z score per case; lines show the means per group.
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2013), the value of this study was the inclusion of a mitochondrial
disease cohort to draw a comparison with PD and healthy ageing. This
is important to increase the understanding of the contribution of mi-
tochondrial dysfunction to SN neuronal survival, as similar properties
such as somatic mtDNA deletions are shared between neurons of aged,
PD and POLG patients with only severe neuronal loss routinely identi-
fied in PD.
One important advantage of our study is the application of multi-
label immunofluorescence. Though RC deficiency in SN neurons of
mitochondrial disease cases has been studied by immunohistochemistry
(Reeve et al., 2013), images acquired from quadruple immuno-
fluorescence allowed the assessment of the varying degree and combi-
nation of RC protein expression, by objectively quantifying the subtle
changes in fluorescent intensity. The variable degrees of complex I and
complex IV expression observed in the SN neurons fits in well with the
expected variability in mtDNA heteroplasmy level, and type of muta-
tion (e.g. deletions of different sites and size) in patients with acquired
mtDNA mutations. Our data revealed significantly higher level of
complex I and complex IV deficiency in SN neurons of mitochondrial
disease patients who harbored mtDNA deletions, compared to the
translational changes that result from mtDNA point mutations in tRNA
genes. We observed high MT-ND4 deletion load and marked complex I
dysfunction in single, large-scale mtDNA deletion and multiple mtDNA
deletions cases. In cases of PD and healthy ageing, we found much less
complex I or complex IV deficiency, of which complex I deficiency is
comparable between these two groups whereas complex IV deficiency is
higher in the healthy ageing group. This is possibly due to the increased
vulnerability of PD neurons to mitochondrial dysfunction or the large
individual diversity within the healthy aged individuals (Supplemen-
tary Fig. 1–1).
High mtDNA total copy number was observed in aged SN neurons
and some PD patients, compared to those from mid-life POLG patients,
despite the fact that these neurons carried high levels of mtDNA dele-
tions. Meanwhile, the relationship of wild type mtDNA copy number
and RC expression showed a tendency for RC protein deficiency to
occur in neurons with low mtDNA copy number. Our data provide
evidence to support the hypothesis of mtDNA copy number as a de-
termining factor in biochemical defect phenotype rather than the het-
eroplasmy level (Durham et al., 2007; Jiang et al., 2017; Stewart and
Chinnery, 2015). Therefore, the SN neuronal loss in some of the POLG
patients was likely a combined consequence of a severe mitochondrial
biochemical defect and low mtDNA copy number. This low mtDNA
copy number could be due to impaired POLG function or compromised
ability to expand the initial mtDNA pool in the early-stages of life
(Stewart et al., 2011; Tzoulis et al., 2014). Limitations in interpretation
of the findings presented in this study is due to the lack of young control
data for reference.
These data further support the beneficial role of an increase in
mtDNA copy number in surviving aged SN neurons, and indicate an
attempt of these neurons to rescue the increasing mtDNA mutation load
which occurs with advancing age (Dolle et al., 2016). Hence, with a
mild RC defect identified in PD neurons, a reduction in TFAM expres-
sion might be a key factor in increasing vulnerability of SN neurons to
mitochondrial dysfunction, and age-related degeneration in these in-
dividuals. A significant decrease in TFAM expression was inferred as a
sign of impaired mitochondrial homeostasis in PD patients. Low TFAM
expression could influence mtDNA D-Loop stability causing impaired
regulation of mtDNA expression (reviewed in Picca and Lezza (2015)),
and dysregulation of mitochondrial proteases, such as TFAM targeted
AAA+ protease, LonP1. These alterations could be further explored by
electrophoretic mobility shift assay (EMSA) of altered mtDNA structure
(Nicholls et al., 2018), transcriptomic analysis of key mitochondrial
genes, and via the measurement of LonP1 expression and activity (Lu
et al., 2013). Another line of evidence supporting the association of
TFAM with SN neuronal adaption, is the increase in TFAM expression in
neurons from patients who carried a mtDNA mutation from early life.
When such cases are compared to PD and healthy aged individual with
accumulated multiple mtDNA deletions, this suggests a contribution of
the nuclear regulation of mitochondrial protein expression in response
to early-onset mitochondrial defects.
Our data showed significantly weaker correlations of PGC-1α with
both COXIV and porin in PD neurons than those in aged controls, in-
dicating impairments in the regulatory signalling of the PGC-1α-mi-
tochondrial axis, as reflected by the significant decrease of TFAM ex-
pression in PD cases. The expression level of PGC-1α protein failed to
respond to TFAM deficiency in an active feedback manner, in fact, it
demonstrated a decrease trend in some PD cases. These findings are
consistent with the low expression level of the PGC-1α gene and its
responsive nuclear-encoded RC genes in PD neurons (Zheng et al.,
2010). However, the intricate interactions between PGC-1α and its
downstream transcriptional factors, and between these transcriptional
factors and their target genes, alongside post-translation modification
of the involved proteins, make it difficult to draw conclusions from
simple measurements of protein expression (reviewed in Islam et al.
(2018)).
5. Conclusion
Overall, all of the data presented here and previously (Dolle et al.,
2016; Grunewald et al., 2016; Reeve et al., 2013) suggests an increased
sensitivity of SN neurons to mitochondrial deficiency and indicates that
this relates in part to TFAM and nuclear retrograde signalling in PD
patients. The decrease in TFAM could be a sign of unstable mtDNA
structure and a collapse of nuclear-mitochondrial regulation, leading to
impaired mtDNA maintenance, which accelerates the neuronal loss. We
hypothesize that impaired nuclear control of mitochondrial biogenesis
is a critical aspect that pushes SN neurons towards early loss due to age-
related mitochondrial dysfunction in PD. Further investigation of the
transcriptional activity of the mitochondrial genome is needed and a
wider screening for related nuclear signal pathways may be implicated.
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